今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ 8-K Current report, items 1.01, 5.03, 5.07, and 9.01 Accession Number: 0001213900-20-040462 Act: 34 Size: 328 KB 网页链接
$Trident(TDAC)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001076809-20-000275 Size: 5 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001076809-20-000276 Size: 9 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001076809-20-000274 Size: 6 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001213900-20-039821 Act: 34 Size: 28 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-20-039822 Act: 34 Size: 28 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-20-039360 Act: 34 Size: 101 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001076809-20-000254 Size: 6 KB 网页链接
$Trident(TDAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-20-038734 Act: 34 Size: 74 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 5.02, 8.01, and 9.01 Accession Number: 0001213900-20-038733 Act: 34 Size: 74 KB 网页链接